Trazodone (Desyrel)

FDA Approved

Serotonin Antagonist & Reuptake Inhibitor | Sleep Aid

Weight: 371.86 Da

Half-life: ~5-9 hours

4 studies

2018 latest

FDA Approved

Dose 25-100 mg at bedtime (sleep)

Frequency Once daily at bedtime

Cycle As prescribed, often ongoing

Storage Room temperature (68-77F). Protect from moisture and light.

Accumulation Plotter

Community Research

Join others researching Trazodone — share findings, ask questions, and learn from real experiences

View Results Aggregated community findings

Discussion Questions & experiences

Submit Your Findings Contribute your research data

Trazodone is a serotonin antagonist and reuptake inhibitor (SARI) that was originally approved by the FDA in 1981 for the treatment of major depressive disorder. However, its clinical use has shifted dramatically over the decades. Today, trazodone is prescribed almost exclusively at low doses as a sleep aid rather than as an antidepressant, making it one of the most commonly prescribed medications for insomnia in the United States. Its popularity stems from the fact that it is non-habit-forming, does not carry the dependence risk associated with benzodiazepines or Z-drugs, and can be used long-term without tolerance development. Trazodone has become particularly well-known in the bodybuilding and performance-enhancement community as a go-to solution for managing insomnia caused by trenbolone and other 19-nortestosterone derivatives, which are notorious for disrupting sleep architecture. Unlike many sleep medications, trazodone actually improves slow-wave sleep (deep sleep) rather than simply inducing sedation, which makes it especially valuable for recovery-focused athletes.

Mechanism of Action

Trazodone's sleep-promoting effects arise from a combination of pharmacological actions across multiple receptor systems. At low doses (25-100 mg), the dominant mechanism is potent antagonism of 5-HT2A serotonin receptors, which promotes slow-wave sleep and reduces sleep latency. Trazodone also blocks histamine H1 receptors, contributing to its sedative properties, and antagonizes alpha-1 adrenergic receptors, which produces additional drowsiness and accounts for the orthostatic hypotension sometimes observed. At higher doses used for depression (150-400 mg), serotonin reuptake inhibition (SRI) becomes more relevant, increasing serotonergic tone in a manner similar to SSRIs but with a distinct receptor profile. The compound is metabolized primarily by CYP3A4 to its active metabolite meta-chlorophenylpiperazine (mCPP), which has serotonin agonist properties. The dose-dependent shift in pharmacological profile explains why trazodone is sedating at low doses but can be activating or cause more typical serotonergic side effects at antidepressant doses.

01 Effective sleep aid that improves sleep onset and sleep maintenance without the dependence risk of benzodiazepines

02 Enhances slow-wave (deep) sleep, which is critical for physical recovery and growth hormone release

03 Non-habit-forming with no significant tolerance development, even with long-term use

04 Widely used and well-tolerated solution for trenbolone-induced and steroid-related insomnia

05 Does not suppress REM sleep the way many other sleep medications do

06 Inexpensive, widely available as a generic, and has decades of safety data

Molecular Data

Molecular Weight

371.86 Da

Type

Triazolopyridine derivative (C19H22ClN5O)

Peak 0.0 mcg

Trough 0.0 mcg

SS Peak 0.0 mcg

SS Trough 0.0 mcg

Research Indications

FDA-Approved

Major Depressive Disorder effective

FDA-approved for the treatment of major depressive disorder, though it is rarely used as a primary antidepressant today due to the availability of SSRIs and SNRIs with more favorable side effect profiles for daytime use. Antidepressant doses range from 150-400 mg/day, significantly higher than the doses used for sleep.

Off-Label (Primary Use)

Insomnia most effective

The most common clinical use of trazodone today. Low doses (25-100 mg) at bedtime reduce sleep onset latency, improve sleep continuity, and enhance slow-wave sleep. Multiple studies support its efficacy, and it is the most frequently prescribed off-label medication for insomnia in the United States. Particularly valued because it avoids the dependence and rebound insomnia associated with benzodiazepines and Z-drugs.

Steroid-Induced Insomnia effective

Extremely popular in the bodybuilding and PED community for managing sleep disruption caused by anabolic steroids, particularly trenbolone (19-nortestosterone derivatives). Trenbolone is notorious for causing severe insomnia and night sweats, and trazodone at 50-100 mg is one of the most reliable and accessible solutions. Its non-addictive profile makes it suitable for use throughout entire steroid cycles.

Off-Label (Secondary)

Anxiety-Related Insomnia effective

Useful for patients whose insomnia is driven by anxiety or racing thoughts at bedtime. The 5-HT2A antagonism and mild anxiolytic properties help quiet mental activity without the cognitive impairment of benzodiazepines.

Insomnia Co-occurring with Depression effective

Often added to an existing SSRI or SNRI regimen specifically to address insomnia. Low-dose trazodone at bedtime can complement a daytime antidepressant without significant drug interaction concerns at typical doses.

Dosing Protocols

Trazodone is available as immediate-release tablets (50 mg, 100 mg, 150 mg, 300 mg) and as an extended-release formulation (Oleptro, 150 mg, 300 mg). For insomnia, immediate-release tablets are used almost exclusively, typically split or prescribed at 25-100 mg doses. The drug is well absorbed orally, and taking it with food increases bioavailability and delays peak concentrations, which can reduce initial dizziness. Peak plasma levels occur approximately 1-2 hours after ingestion on an empty stomach.

Goal	Dose	Frequency	Route
Sleep Aid - Starting Dose	25-50 mg	Once at bedtime	Oral tablet
Sleep Aid - Standard Dose	50-100 mg	Once at bedtime	Oral tablet
Antidepressant - Therapeutic Dose	150-400 mg/day	Divided doses or once daily (extended-release)	Oral tablet

Interactions

SSRIs (e.g., Sertraline, Fluoxetine)

Combining trazodone with SSRIs increases serotonergic activity and raises the theoretical risk of serotonin syndrome, though this combination is commonly used in clinical practice at low trazodone doses for insomnia. Monitor for symptoms including agitation, tremor, hyperthermia, and myoclonus. The risk is dose-dependent and generally low at sleep-aid doses (25-100 mg).

monitor

MAOIs

Concurrent use of trazodone with monoamine oxidase inhibitors (MAOIs) is contraindicated due to a significant risk of serotonin syndrome, a potentially life-threatening condition. Allow a minimum 14-day washout period between discontinuing an MAOI and starting trazodone, and vice versa.

avoid

Phenibut

Both trazodone and phenibut have sedative properties. Combining them can result in excessive CNS depression, including profound drowsiness, impaired coordination, and respiratory depression at high doses. If used together, start with lower doses of both and avoid combining with alcohol or other CNS depressants.

monitor

Alcohol

Alcohol potentiates the sedative and CNS-depressant effects of trazodone. The combination increases the risk of excessive drowsiness, dizziness, orthostatic hypotension, and impaired motor coordination. Patients should be counseled to limit or avoid alcohol use, particularly within a few hours of taking trazodone.

monitor

What to Expect

30-60 minutes

Onset of drowsiness and sedation. Most individuals begin to feel sleepy within 30-60 minutes of taking trazodone, making it important to take the dose when ready for bed. Taking it with a small snack may slightly delay onset but improves tolerability.

1-2 hours

Peak plasma concentration reached. Maximum sedative effect is felt. Sleep onset typically occurs during this window. Users report a calm, natural-feeling drowsiness rather than the heavy, forced sedation of benzodiazepines.

3-5 hours

Deep sleep maintenance. Trazodone's 5-HT2A antagonism supports sustained slow-wave sleep during the first half of the night, which is the most restorative phase of sleep for physical recovery.

5-9 hours

Drug elimination phase. Trazodone is cleared with a half-life of 5-9 hours. At low doses (25-50 mg), most individuals wake without residual sedation. At higher doses (75-100 mg), some morning grogginess is possible, particularly during the first few days of use.

1-2 weeks

Consistent use establishes a reliable sleep pattern. Unlike benzodiazepines, efficacy is maintained without dose escalation. Any initial morning drowsiness typically resolves as the body adjusts to the medication.

Side Effects & Safety

Common Side Effects

Morning drowsiness or grogginess (dose-dependent, more common above 50 mg)
Dry mouth
Dizziness or lightheadedness, particularly upon standing (orthostatic hypotension)
Headache
Nausea (reduced by taking with food)
Blurred vision

Stop Signs - Discontinue if:

Prolonged or painful erection lasting more than 4 hours (priapism -- seek emergency medical attention immediately)
Signs of serotonin syndrome: agitation, confusion, rapid heart rate, elevated body temperature, muscle rigidity, tremor
Fainting or severe lightheadedness upon standing
Irregular heartbeat, chest pain, or palpitations
Allergic reaction: rash, swelling of the face or throat, difficulty breathing

Contraindications

Known hypersensitivity to trazodone
Concurrent use of MAOIs or use within 14 days of MAOI discontinuation
History of priapism or conditions predisposing to priapism (e.g., sickle cell disease, multiple myeloma, leukemia)
Severe hepatic impairment (dose adjustment required in moderate impairment)
Recent myocardial infarction or unstable cardiac conditions
Pregnancy, particularly first trimester (Category C; limited human data)

References

Trazodone for Insomnia: A Systematic Review

Yi, X.Y., Ni, S.F., Ghadami, M.R., et al.

Frontiers in Pharmacology (2018)

Systematic review examining trazodone's efficacy for insomnia across multiple clinical populations. Found consistent evidence that low-dose trazodone (25-150 mg) improves sleep quality, reduces sleep onset latency, and enhances slow-wave sleep, supporting its widespread off-label use as a first-line insomnia treatment.
The Use of Trazodone as a Hypnotic: A Critical Review

Mendelson, W.B.

Journal of Clinical Psychiatry (2005)

Critical review of trazodone's use as a hypnotic, noting that despite limited large-scale randomized controlled trials specifically for insomnia, trazodone had become the most commonly prescribed agent for insomnia in the United States by the early 2000s, largely due to clinician experience and its favorable safety profile relative to benzodiazepines.
Trazodone: Pharmacology, Clinical Uses, and Adverse Effects

Stahl, S.M.

Journal of Clinical Psychiatry (2009)

Comprehensive pharmacological review describing trazodone's dose-dependent mechanism of action: 5-HT2A antagonism and histamine blockade predominate at low doses (producing sedation), while serotonin reuptake inhibition becomes relevant only at higher antidepressant doses, explaining the clinical divergence between its use as a sleep aid and as an antidepressant.
Low-Dose Trazodone Lowers the Risk of Admission for Benzodiazepine/Z-Drug Use

Jaffer, K.Y., Chang, T., Vanle, B., et al.

Journal of Clinical Medicine (2017)

Study demonstrating that low-dose trazodone use for insomnia was associated with reduced need for benzodiazepine and Z-drug prescriptions, supporting the role of trazodone as a safer alternative for long-term insomnia management without the risks of dependence, tolerance, and withdrawal associated with GABAergic hypnotics.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.